OptiMedica Launches Suite of Integrated Practice Solutions for the Pascal Photocoagulator.SANTA CLARA, Calif. -- OptiMedica([R]) Corporation, a leading developer of ophthalmic therapeutic devices, today introduced a new portfolio of products, including the Pascal Laser Indirect Ophthalmoscope (LIO) which was granted marketing clearance by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. this month, Automated LaserLog[TM] with treatment summary printout and Intelligent Device Management. These products increase treatment options and efficiencies for the ophthalmic practice and will be showcased this week at the 110th annual American Academy of Ophthalmology The American Academy of Ophthalmology (AAO) is a medical association of ophthalmologists–medical doctors (MDs) specializing in eye care and surgery). The group is based in San Francisco, California. (AAO AAO American Association of Orthodontists; American Academy of Ophthalmology; American Academy of Otolaryngology; American Academy of Osteopathy. AAO ) annual meeting in Las Vegas. "OptiMedica is committed to delivering the ultimate customer experience," said Dr. David Mordaunt, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of OptiMedica. "This includes integrating the best in service with best in products to improve productivity of the entire practice." The Pascal LIO incorporates superior optics, functional ergonomics and easy-to-use controls. Its built-in device monitoring system provides an added level of safety by designating which delivery method is active and allowing seamless transition between the LIO and the slit lamp. It broadens the use of the Pascal Photocoagulator for all treatment modalities and situations. LaserLog saves time and effort by automating treatment documentation and providing printout capability. This software is compatible with any standard PC, facilitating comprehensive documentation of treatment summary and patient ID information as well as physician and CPT CPT See: Carriage Paid To codes. In addition, LaserLog increases accuracy and helps avoid missed billing opportunities. Intelligent Device Management includes real-time online monitoring, diagnosis and troubleshooting. Together, these services provide customers with immediate access to engineering and product management support to ensure a smooth running practice. OptiMedica can be visited at booth number 2672 at the Sands Expo/Venetian in Las Vegas from November 11 - 13 during the AAO annual meeting. More information about the Pascal Photocoagulator is available at www.opitmedica.com. About OptiMedica OptiMedica Corp. develops and markets medical devices that treat ophthalmic disorders such as diabetic retinopathy, age-related macular degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. , retinal vascular occlusive occlusive /oc·clu·sive/ (o-kloo´siv) pertaining to or causing occlusion. oc·clu·sive adj. 1. Occluding or tending to occlude. 2. disease and retinal tears and detachments. OptiMedica holds the exclusive license to the PASCAL[R] (PAttern SCAn Laser) method of photocoagulation photocoagulation /pho·to·co·ag·u·la·tion/ (-ko-ag?u-la´shun) condensation of protein material by the controlled use of an intense beam of light (e.g. and its associated technologies, which are FDA approved to treat a variety of retinal conditions. OptiMedica was founded in 2004 in Santa Clara, Calif. and is funded by Kleiner, Perkins, Caufield & Byers and Alloy Ventures. For more information, please visit www.optimedica.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion